Publication list - Publika - Scientific publications from Oslo University Hospital

Publications by Ruth Holm

221 publications found

Original articles

Dahlgren D, Venczel M, Ridoux JP, Skjöld C, Müllertz A, Holm R, Augustijns P, Hellström PM, Lennernäs H (2021)
Fasted and fed state human duodenal fluids: Characterization, drug solubility, and comparison to simulated fluids and with human bioavailability
Eur J Pharm Biopharm, 163, 240-251
DOI 10.1016/j.ejpb.2021.04.005, PubMed 33872761

Jonsson M, Fjeldbo CS, Holm R, Stokke T, Kristensen GB, Lyng H (2019)
Mitochondrial Function of CKS2 Oncoprotein Links Oxidative Phosphorylation with Cell Division in Chemoradioresistant Cervical Cancer
Neoplasia, 21 (4), 353-362
DOI 10.1016/j.neo.2019.01.002, PubMed 30856376

Wang Z, Førsund MS, Trope CG, Nesland JM, Holm R, Slipicevic A (2018)
Evaluation of CHK1 activation in vulvar squamous cell carcinoma and its potential as a therapeutic target in vitro
Cancer Med, 7 (8), 3955-3964
DOI 10.1002/cam4.1638, PubMed 29963769

Davidson B, Holth A, Wang Z, Hellsylt E, Tropé CG, Hetland Falkenthal TE, Holm R (2018)
Expression of 14-3-3 sigma and eta proteins is unrelated to survival in metastatic high-grade serous carcinoma
APMIS, 126 (4), 309-313
DOI 10.1111/apm.12816, PubMed 29464778

Holm R, Schou H, Petersen HR, Horntvedt M (2018)
Behavioral performance during vibration and shock for a tactical grade IMU
PR DGON INET SENS SY, P10

Larsen AT, Holm R, Müllertz A (2017)
Solution or suspension - Does it matter for lipid based systems? In vivo studies of chase dosing lipid vehicles with aqueous suspensions of a poorly soluble drug
Eur J Pharm Biopharm, 117, 308-314
DOI 10.1016/j.ejpb.2017.04.023, PubMed 28465239

Holm R, Schou H, Petersen HR, Normann S (2017)
Sharing historical data on tactical-grade MEMS-based IMUs delivered to global customers for almost a decade
2017 DGON INERTIAL SENSORS AND SYSTEMS (ISS), P10

Yu D, Holm R, Goscinski MA, Trope CG, Nesland JM, Suo Z (2016)
Prognostic and clinicopathological significance of Cacna2d1 expression in epithelial ovarian cancers: a retrospective study
Am J Cancer Res, 6 (9), 2088-2097
PubMed 27725913

Eide HA, Halvorsen AR, Bjaanæs MM, Piri H, Holm R, Solberg S, Jørgensen L, Brustugun OT, Kiserud CE, Helland Å (2016)
The MYCN-HMGA2-CDKN2A pathway in non-small cell lung carcinoma--differences in histological subtypes
BMC Cancer, 16, 71
DOI 10.1186/s12885-016-2104-9, PubMed 26858029

Huang R, Li X, Holm R, Trope CG, Nesland JM, Suo Z (2015)
The expression of aldehyde dehydrogenase 1 (ALDH1) in ovarian carcinomas and its clinicopathological associations: a retrospective study
BMC Cancer, 15, 502
DOI 10.1186/s12885-015-1513-5, PubMed 26148881

Wang Z, Slipicevic A, Førsund M, Trope CG, Nesland JM, Holm R (2015)
Expression of CDK1(Tyr15), pCDK1(Thr161), Cyclin B1 (total) and pCyclin B1(Ser126) in vulvar squamous cell carcinoma and their relations with clinicopatological features and prognosis
PLoS One, 10 (4), e0121398
DOI 10.1371/journal.pone.0121398, PubMed 25849598

Flørenes VA, Emilsen E, Dong HP, Førsund M, Holm R, Slipicevic A (2015)
Cellular localization of CIP2A determines its prognostic impact in superficial spreading and nodular melanoma
Cancer Med, 4 (6), 903-13
DOI 10.1002/cam4.425, PubMed 25663244

Skrbo N, Hjortland GO, Kristian A, Holm R, Nord S, Prasmickaite L, Engebraaten O, Mælandsmo GM, Sørlie T, Andersen K (2014)
Differential in vivo tumorigenicity of distinct subpopulations from a luminal-like breast cancer xenograft
PLoS One, 9 (11), e113278
DOI 10.1371/journal.pone.0113278, PubMed 25419568

Huang R, Wu D, Yuan Y, Li X, Holm R, Trope CG, Nesland JM, Suo Z (2014)
CD117 expression in fibroblasts-like stromal cells indicates unfavorable clinical outcomes in ovarian carcinoma patients
PLoS One, 9 (11), e112209
DOI 10.1371/journal.pone.0112209, PubMed 25380303

Wu Q, Shi H, Holm R, Li X, Trope C, Nesland JM, Suo Z (2014)
Aldehyde dehydrogenase-1 predicts favorable prognosis in patients with vulvar squamous cell carcinoma
Anticancer Res, 34 (2), 859-65
PubMed 24511023

Huang R, Ma Y, Holm R, Trope CG, Nesland JM, Suo Z (2013)
Sex hormone-binding globulin (SHBG) expression in ovarian carcinomas and its clinicopathological associations
PLoS One, 8 (12), e83238
DOI 10.1371/journal.pone.0083238, PubMed 24386165

Dhakal HP, Nesland JM, Førsund M, Trope CG, Holm R (2013)
Primary tumor vascularity, HIF-1α and VEGF expression in vulvar squamous cell carcinomas: their relationships with clinicopathological characteristics and prognostic impact
BMC Cancer, 13, 506
DOI 10.1186/1471-2407-13-506, PubMed 24165149

Ragnum HB, Røe K, Holm R, Vlatkovic L, Nesland JM, Aarnes EK, Ree AH, Flatmark K, Seierstad T, Lilleby W, Lyng H (2013)
Hypoxia-independent downregulation of hypoxia-inducible factor 1 targets by androgen deprivation therapy in prostate cancer
Int J Radiat Oncol Biol Phys, 87 (4), 753-60
DOI 10.1016/j.ijrobp.2013.07.023, PubMed 24035332

Kristian A, Nilsen LB, Røe K, Revheim ME, Engebråten O, Mælandsmo GM, Holm R, Malinen E, Seierstad T (2013)
Dynamic (18) F-FDG PET for Assessment of Tumor Physiology in Two Breast Carcinoma Xenografts
Nucl Med Mol Imaging, 47 (3), 173-80
DOI 10.1007/s13139-013-0211-y, PubMed 24900104

Magnussen GI, Hellesylt E, Nesland JM, Trope CG, Flørenes VA, Holm R (2013)
High expression of wee1 is associated with malignancy in vulvar squamous cell carcinoma patients
BMC Cancer, 13, 288
DOI 10.1186/1471-2407-13-288, PubMed 23767999

Lando M, Wilting SM, Snipstad K, Clancy T, Bierkens M, Aarnes EK, Holden M, Stokke T, Sundfør K, Holm R, Kristensen GB, Steenbergen RD, Lyng H (2013)
Identification of eight candidate target genes of the recurrent 3p12-p14 loss in cervical cancer by integrative genomic profiling
J Pathol, 230 (1), 59-69
DOI 10.1002/path.4168, PubMed 23335387

Revheim ME, Kristian A, Malinen E, Bruland ØS, Berner JM, Holm R, Joensuu H, Seierstad T (2013)
Intermittent and continuous imatinib in a human GIST xenograft model carrying KIT exon 17 resistance mutation D816H
Acta Oncol, 52 (4), 776-82
DOI 10.3109/0284186X.2013.770920, PubMed 23480638

Holm R, Førsund M, Nguyen MT, Nesland JM, Trope CG (2013)
Expression of p15INK⁴b and p57KIP² and relationship with clinicopathological features and prognosis in patients with vulvar squamous cell carcinoma
PLoS One, 8 (4), e61273
DOI 10.1371/journal.pone.0061273, PubMed 23580324

Baumbusch LO, Helland Å, Wang Y, Liestøl K, Schaner ME, Holm R, Etemadmoghadam D, Alsop K, Brown P, Australian Ovarian Cancer Study Group, Mitchell G, Fereday S, DeFazio A, Bowtell DD, Kristensen GB, Lingjærde OC, Børresen-Dale AL (2013)
High levels of genomic aberrations in serous ovarian cancers are associated with better survival
PLoS One, 8 (1), e54356
DOI 10.1371/journal.pone.0054356, PubMed 23372714

Dhakal HP, Naume B, Synnestvedt M, Borgen E, Kaaresen R, Schlichting E, Wiedswang G, Bassarova A, Holm R, Giercksky KE, Nesland JM (2012)
Expression of cyclooxygenase-2 in invasive breast carcinomas and its prognostic impact
Histol Histopathol, 27 (10), 1315-25
DOI 10.14670/HH-27.1315, PubMed 22936450

Halle C, Andersen E, Lando M, Aarnes EK, Hasvold G, Holden M, Syljuåsen RG, Sundfør K, Kristensen GB, Holm R, Malinen E, Lyng H (2012)
Hypoxia-induced gene expression in chemoradioresistant cervical cancer revealed by dynamic contrast-enhanced MRI
Cancer Res, 72 (20), 5285-95
DOI 10.1158/0008-5472.CAN-12-1085, PubMed 22890239

Dhakal HP, Naume B, Synnestvedt M, Borgen E, Kaaresen R, Schlichting E, Wiedswang G, Bassarova A, Holm R, Giercksky KE, Nesland JM (2012)
Expression of vascular endothelial growth factor and vascular endothelial growth factor receptors 1 and 2 in invasive breast carcinoma: prognostic significance and relationship with markers for aggressiveness
Histopathology, 61 (3), 350-64
DOI 10.1111/j.1365-2559.2012.04223.x, PubMed 22690749

Liang D, Ma Y, Liu J, Trope CG, Holm R, Nesland JM, Suo Z (2012)
The hypoxic microenvironment upgrades stem-like properties of ovarian cancer cells
BMC Cancer, 12, 201
DOI 10.1186/1471-2407-12-201, PubMed 22642602

Slipicevic A, Holm R, Emilsen E, Ree Rosnes AK, Welch DR, Mælandsmo GM, Flørenes VA (2012)
Cytoplasmic BRMS1 expression in malignant melanoma is associated with increased disease-free survival
BMC Cancer, 12, 73
DOI 10.1186/1471-2407-12-73, PubMed 22356677

Magnussen GI, Holm R, Emilsen E, Rosnes AK, Slipicevic A, Flørenes VA (2012)
High expression of Wee1 is associated with poor disease-free survival in malignant melanoma: potential for targeted therapy
PLoS One, 7 (6), e38254
DOI 10.1371/journal.pone.0038254, PubMed 22719872

Sigstad E, Paus E, Bjøro T, Berner A, Grøholt KK, Jørgensen LH, Sobrinho-Simões M, Holm R, Warren DJ (2011)
The new molecular markers DDIT3, STT3A, ARG2 and FAM129A are not useful in diagnosing thyroid follicular tumors
Mod Pathol, 25 (4), 537-47
DOI 10.1038/modpathol.2011.188, PubMed 22157935

Schee K, Flatmark K, Holm R, Boye K, Paus E (2011)
Investigation of nonspecific cross-reacting antigen 2 as a prognostic biomarker in bone marrow plasma from colorectal cancer patients
Tumour Biol, 33 (1), 73-83
DOI 10.1007/s13277-011-0247-5, PubMed 22006279

Stratford EW, Castro R, Wennerstrom A, Holm R, Munthe E, Lauvrak S, Bjerkehagen B, Myklebost O (2011)
Liposarcoma Cells with Aldefluor and CD133 Activity have a Cancer Stem Cell Potential
Clin Sarcoma Res, 1 (1), 8
DOI 10.1186/2045-3329-1-8, PubMed 22612877

Halle C, Lando M, Svendsrud DH, Clancy T, Holden M, Sundfør K, Kristensen GB, Holm R, Lyng H (2011)
Membranous expression of ectodomain isoforms of the epidermal growth factor receptor predicts outcome after chemoradiotherapy of lymph node-negative cervical cancer
Clin Cancer Res, 17 (16), 5501-12
DOI 10.1158/1078-0432.CCR-11-0297, PubMed 21737508

Engesæter BO, Sathermugathevan M, Hellenes T, Engebråten O, Holm R, Flørenes VA, Mælandsmo GM (2011)
Targeting inhibitor of apoptosis proteins in combination with dacarbazine or TRAIL in melanoma cells
Cancer Biol Ther, 12 (1), 47-58
DOI 10.4161/cbt.12.1.15714, PubMed 21508672

Halle C, Lando M, Sundfør K, Kristensen GB, Holm R, Lyng H (2011)
Phosphorylation of EGFR measured with in situ proximity ligation assay: relationship to EGFR protein level and gene dosage in cervical cancer
Radiother Oncol, 101 (1), 152-7
DOI 10.1016/j.radonc.2011.05.052, PubMed 21680035

Helland Å, Anglesio MS, George J, Cowin PA, Johnstone CN, House CM, Sheppard KE, Etemadmoghadam D, Melnyk N, Rustgi AK, Phillips WA, Johnsen H, Holm R, Kristensen GB, Birrer MJ, Australian Ovarian Cancer Study Group, Pearson RB, Børresen-Dale AL, Huntsman DG, deFazio A, Creighton CJ, Smyth GK, Bowtell DD (2011)
Deregulation of MYCN, LIN28B and LET7 in a molecular subtype of aggressive high-grade serous ovarian cancers
PLoS One, 6 (4), e18064
DOI 10.1371/journal.pone.0018064, PubMed 21533284

Wang Z, Nesland JM, Suo Z, Trope CG, Holm R (2011)
The prognostic value of 14-3-3 isoforms in vulvar squamous cell carcinoma cases: 14-3-3β and ε are independent prognostic factors for these tumors
PLoS One, 6 (9), e24843
DOI 10.1371/journal.pone.0024843, PubMed 21935479

Khouja MH, Baekelandt M, Sarab A, Nesland JM, Holm R (2010)
Limitations of tissue microarrays compared with whole tissue sections in survival analysis
Oncol Lett, 1 (5), 827-831
DOI 10.3892/ol_00000145, PubMed 22966388

Wang Z, He W, Yang G, Wang J, Wang Z, Nesland JM, Holm R, Suo Z (2010)
Decreased expression of GST pi is correlated with a poor prognosis in human esophageal squamous carcinoma
BMC Cancer, 10, 352
DOI 10.1186/1471-2407-10-352, PubMed 20602752

Wang Z, Trope CG, Flørenes VA, Suo Z, Nesland JM, Holm R (2010)
Overexpression of CDC25B, CDC25C and phospho-CDC25C (Ser216) in vulvar squamous cell carcinomas are associated with malignant features and aggressive cancer phenotypes
BMC Cancer, 10, 233
DOI 10.1186/1471-2407-10-233, PubMed 20500813

Callen DF, Ricciardelli C, Butler M, Stapleton A, Stahl J, Kench JG, Horsfall DJ, Tilley WD, Schulz R, Nesland JM, Neilsen PM, Kumar R, Holm R (2010)
Co-expression of the androgen receptor and the transcription factor ZNF652 is related to prostate cancer outcome
Oncol Rep, 23 (4), 1045-52
DOI 10.3892/or_00000731, PubMed 20204290

Evang JA, Borota OC, Melum E, Holm R, Ramm-Pettersen J, Bollerslev J, Berg JP (2010)
HDAC2 expression and variable number of repeats in exon 1 of the HDAC2 gene in corticotroph adenomas
Clin Endocrinol (Oxf), 73 (2), 229-35
DOI 10.1111/j.1365-2265.2010.03805.x, PubMed 20346000

Fedorcsák P, Polec A, Ráki M, Holm R, Jebsen P, Abyholm T (2010)
Differential release of matrix metalloproteinases and tissue inhibitors of metalloproteinases by human granulosa-lutein cells and ovarian leukocytes
Endocrinology, 151 (3), 1290-8
DOI 10.1210/en.2009-0605, PubMed 20051489

Holm R, Ali T, Svendsrud DH, Nesland JM, Kristensen GB, Lyng H (2009)
Expression of 14-3-3sigma in cervical squamous cell carcinomas: relationship with clinical outcome
Oncol Rep, 22 (1), 11-5
DOI 10.3892/or_00000399, PubMed 19513498

Wang Z, Tropè CG, Suo Z, Trøen G, Yang G, Nesland JM, Holm R (2008)
The clinicopathological and prognostic impact of 14-3-3 sigma expression on vulvar squamous cell carcinomas
BMC Cancer, 8, 308
DOI 10.1186/1471-2407-8-308, PubMed 18950492

Holm R, de Putte GV, Suo Z, Lie AK, Kristensen GB (2008)
Expressions of EphA2 and EphrinA-1 in early squamous cell cervical carcinomas and their relation to prognosis
Int J Med Sci, 5 (3), 121-6
DOI 10.7150/ijms.5.121, PubMed 18566674

Holm R, Kraus I, Skomedal H, Langerød A, Kristensen GB, Lyng H (2008)
Human papillomavirus DNA and e6/e7 mRNA status in relation to survival of patients treated for cervical squamous cell carcinoma
Open Virol J, 2, 74-81
DOI 10.2174/1874357900802010074, PubMed 19440467

Khouja MH, Baekelandt M, Nesland JM, Holm R (2007)
The clinical importance of Ki-67, p16, p14, and p57 expression in patients with advanced ovarian carcinoma
Int J Gynecol Pathol, 26 (4), 418-25
DOI 10.1097/pgp.0b013e31804216a0, PubMed 17885492

Holm R, Knopp S, Kumar R, Lee J, Nesland JM, Tropè C, Callen DF (2007)
Expression of ZNF652, a novel zinc finger protein, in vulvar carcinomas and its relation to prognosis
J Clin Pathol, 61 (1), 59-63
DOI 10.1136/jcp.2006.045864, PubMed 17468294

Holm R, Knopp S, Suo Z, Tropè C, Nesland JM (2006)
Expression of EphA2 and EphrinA-1 in vulvar carcinomas and its relation to prognosis
J Clin Pathol, 60 (10), 1086-91
DOI 10.1136/jcp.2006.041194, PubMed 17158642

Lyng H, Brøvig RS, Svendsrud DH, Holm R, Kaalhus O, Knutstad K, Oksefjell H, Sundfør K, Kristensen GB, Stokke T (2006)
Gene expressions and copy numbers associated with metastatic phenotypes of uterine cervical cancer
BMC Genomics, 7, 268
DOI 10.1186/1471-2164-7-268, PubMed 17054779

Knopp S, Nesland JM, Tropé C, Holm R (2006)
p14ARF, a prognostic predictor in HPV-negative vulvar carcinoma
Am J Clin Pathol, 126 (2), 266-76
DOI 10.1309/e9e8y9wg5qe3lk29, PubMed 16891203

Kraus I, Molden T, Holm R, Lie AK, Karlsen F, Kristensen GB, Skomedal H (2006)
Presence of E6 and E7 mRNA from human papillomavirus types 16, 18, 31, 33, and 45 in the majority of cervical carcinomas
J Clin Microbiol, 44 (4), 1310-7
DOI 10.1128/JCM.44.4.1310-1317.2006, PubMed 16597856

Slipicevic A, Holm R, Nguyen MT, Bøhler PJ, Davidson B, Flørenes VA (2005)
Expression of activated Akt and PTEN in malignant melanomas: relationship with clinical outcome
Am J Clin Pathol, 124 (4), 528-36
DOI 10.1309/YT58WWMTA6YR1PRV, PubMed 16146807

Han L, Dong Z, Qiao Y, Kristensen GB, Holm R, Nesland JM, Suo Z (2005)
The clinical significance of EphA2 and Ephrin A-1 in epithelial ovarian carcinomas
Gynecol Oncol, 99 (2), 278-86
DOI 10.1016/j.ygyno.2005.06.036, PubMed 16061279

Knopp S, Holm R, Tropé C, Nesland JM (2005)
Occult lymph node metastases in early stage vulvar carcinoma patients
Gynecol Oncol, 99 (2), 383-7
DOI 10.1016/j.ygyno.2005.06.023, PubMed 16051338

Knopp S, Bjørge T, Nesland JM, Tropé C, Holm R (2005)
Cyclins D1, D3, E, and A in vulvar carcinoma patients
Gynecol Oncol, 97 (3), 733-9
DOI 10.1016/j.ygyno.2005.03.025, PubMed 15894358

Van de Putte G, Holm R, Lie AK, Baekelandt M, Kristensen GB (2005)
Markers of apoptosis in stage IB squamous cervical carcinoma
J Clin Pathol, 58 (6), 590-4
DOI 10.1136/jcp.2004.021220, PubMed 15917408

Wang Y, Helland A, Holm R, Kristensen GB, Børresen-Dale AL (2005)
PIK3CA mutations in advanced ovarian carcinomas
Hum Mutat, 25 (3), 322
DOI 10.1002/humu.9316, PubMed 15712344

Holm S, Hovind OB, Rostad S, Holm R (2005)
Indoors data communications using airborne ultrasound
INT CONF ACOUST SPEE, 957-960

Knopp S, Bjørge T, Nesland JM, Tropé C, Scheistrøen M, Holm R (2004)
p16INK4a and p21Waf1/Cip1 expression correlates with clinical outcome in vulvar carcinomas
Gynecol Oncol, 95 (1), 37-45
DOI 10.1016/j.ygyno.2004.07.026, PubMed 15385108

Flørenes VA, Maelandsmo GM, Holm R, Reich R, Lazarovici P, Davidson B (2004)
Expression of activated TrkA protein in melanocytic tumors: relationship to cell proliferation and clinical outcome
Am J Clin Pathol, 122 (3), 412-20
DOI 10.1309/CHFH-EYAT-44WW-P7J3, PubMed 15362372

Wu D, Suo Z, Kristensen GB, Li S, Troen G, Holm R, Nesland JM (2004)
Prognostic value of EphA2 and EphrinA-1 in squamous cell cervical carcinoma
Gynecol Oncol, 94 (2), 312-9
DOI 10.1016/j.ygyno.2004.05.019, PubMed 15297167

Van de Putte G, Kristensen GB, Baekelandt M, Lie AK, Holm R (2004)
E-cadherin and catenins in early squamous cervical carcinoma
Gynecol Oncol, 94 (2), 521-7
DOI 10.1016/j.ygyno.2004.05.046, PubMed 15297198

Andersen K, Nesland JM, Holm R, Flørenes VA, Fodstad Ø, Maelandsmo GM (2004)
Expression of S100A4 combined with reduced E-cadherin expression predicts patient outcome in malignant melanoma
Mod Pathol, 17 (8), 990-7
DOI 10.1038/modpathol.3800151, PubMed 15133476

Wang Y, Kringen P, Kristensen GB, Holm R, Baekelandt MM, Olivier M, Skomedal H, Hainaut P, Tropé CG, Abeler VM, Nesland JM, Børresen-Dale AL, Helland A (2004)
Effect of the codon 72 polymorphism (c.215G>C, p.Arg72Pro) in combination with somatic sequence variants in the TP53 gene on survival in patients with advanced ovarian carcinoma
Hum Mutat, 24 (1), 21-34
DOI 10.1002/humu.20055, PubMed 15221786

Wang Y, Helland A, Holm R, Skomedal H, Abeler VM, Danielsen HE, Tropé CG, Børresen-Dale AL, Kristensen GB (2004)
TP53 mutations in early-stage ovarian carcinoma, relation to long-term survival
Br J Cancer, 90 (3), 678-85
DOI 10.1038/sj.bjc.6601537, PubMed 14760384

Van de Putte G, Kristensen GB, Lie AK, Baekelandt M, Holm R (2004)
Cyclins and proliferation markers in early squamous cervical carcinoma
Gynecol Oncol, 92 (1), 40-6
DOI 10.1016/j.ygyno.2003.10.022, PubMed 14751136

Wu D, Qiao Y, Kristensen GB, Li S, Troen G, Holm R, Nesland JM, Suo Z (2004)
Prognostic significance of dysadherin expression in cervical squamous cell carcinoma
Pathol Oncol Res, 10 (4), 212-8
DOI 10.1007/BF03033763, PubMed 15619642

Jørgensen K, Holm R, Maelandsmo GM, Flørenes VA (2003)
Expression of activated extracellular signal-regulated kinases 1/2 in malignant melanomas: relationship with clinical outcome
Clin Cancer Res, 9 (14), 5325-31
PubMed 14614017

Maelandsmo GM, Holm R, Nesland JM, Fodstad Ø, Flørenes VA (2003)
Reduced beta-catenin expression in the cytoplasm of advanced-stage superficial spreading malignant melanoma
Clin Cancer Res, 9 (9), 3383-8
PubMed 12960126

Bukholm IR, Bukholm G, Holm R, Nesland JM (2003)
Association between histology grade, expression of HsMCM2, and cyclin A in human invasive breast carcinomas
J Clin Pathol, 56 (5), 368-73
DOI 10.1136/jcp.56.5.368, PubMed 12719458

van de Putte G, Holm R, Lie AK, Tropé CG, Kristensen GB (2003)
Expression of p27, p21, and p16 protein in early squamous cervical cancer and its relation to prognosis
Gynecol Oncol, 89 (1), 140-7
DOI 10.1016/s0090-8258(03)00010-6, PubMed 12694668

Reed W, Sandstad B, Holm R, Nesland JM (2003)
The prognostic impact of hormone receptors and c-erbB-2 in pregnancy-associated breast cancer and their correlation with BRCA1 and cell cycle modulators
Int J Surg Pathol, 11 (2), 65-74
DOI 10.1177/106689690301100201, PubMed 12754622

Skotheim RI, Abeler VM, Nesland JM, Fosså SD, Holm R, Wagner U, Flørenes VA, Aass N, Kallioniemi OP, Lothe RA (2003)
Candidate genes for testicular cancer evaluated by in situ protein expression analyses on tissue microarrays
Neoplasia, 5 (5), 397-404
DOI 10.1016/s1476-5586(03)80042-8, PubMed 14670177

Skomedal H, Forus A, Holm R (2003)
Deregulation of D-type cyclins in uterine cancers. Cyclin D1/D3 is differentially expressed in cervical cancer
Anticancer Res, 23 (5A), 3929-35
PubMed 14666699

Lopes JM, Nesland JM, Reis-Filho JS, Holm R (2002)
Differential Ki67 and bcl-2 immunoexpression in solid-glandular and spindle cell components of biphasic synovial sarcoma: a double immunostaining assessment with cytokeratin and vimentin
Histopathology, 40 (5), 464-71
DOI 10.1046/j.1365-2559.2002.01371.x, PubMed 12010367

Kraggerud SM, Aman P, Holm R, Stenwig AE, Fosså SD, Nesland JM, Lothe RA (2002)
Alterations of the fragile histidine triad gene, FHIT, and its encoded products contribute to testicular germ cell tumorigenesis
Cancer Res, 62 (2), 512-7
PubMed 11809703

Røtterud R, Pettersen EO, Berner A, Holm R, Olsen DR, Fosså SD (2002)
Cell cycle inhibitors and outcome after radiotherapy in bladder cancer patients
Acta Oncol, 41 (5), 463-70
DOI 10.1080/028418602320405069, PubMed 12442923

Flørenes VA, Maelandsmo GM, Faye R, Nesland JM, Holm R (2001)
Cyclin A expression in superficial spreading malignant melanomas correlates with clinical outcome
J Pathol, 195 (5), 530-6
DOI 10.1002/path.1007, PubMed 11745687

Røtterud R, Berner A, Holm R, Skovlund E, Fosså SD (2001)
p53, p21 and mdm2 expression vs the response to radiotherapy in transitional cell carcinoma of the bladder
BJU Int, 88 (3), 202-8
DOI 10.1046/j.1464-410x.2001.02268.x, PubMed 11488730

Holm R, Skovlund E, Skomedal H, Flørenes VA, Tanum G (2001)
Reduced expression of p21WAF1 is an indicator of malignant behaviour in anal carcinomas
Histopathology, 39 (1), 43-9
DOI 10.1046/j.1365-2559.2001.01161.x, PubMed 11454043

Dai H, Holm R, Kristensen GB, Abeler VM, Børresen-Dale AL, Helland A (2001)
Fibroblast growth factor receptor 3 (FGFR3) - analyses of the S249C mutation and protein expression in primary cervical carcinomas
Anal Cell Pathol, 23 (2), 45-9
DOI 10.1155/2001/521873, PubMed 11904459

Baekelandt M, Holm R, Nesland JM, Tropé CG, Kristensen GB (2000)
Expression of apoptosis-related proteins is an independent determinant of patient prognosis in advanced ovarian cancer
J Clin Oncol, 18 (22), 3775-81
DOI 10.1200/JCO.2000.18.22.3775, PubMed 11078490

Helland A, Kraggerud SM, Kristensen GB, Holm R, Abeler VM, Huebner K, Borresen-Dale AL, Lothe RA (2000)
Primary cervical carcinomas show 2 common regions of deletion at 3P, 1 within the FHIT gene: evaluation of allelic imbalance at FHIT, RB1 and TP53 in relation to survival
Int J Cancer, 88 (2), 217-22
DOI 10.1002/1097-0215(20001015)88:2<217::aid-ijc11>3.0.co;2-i, PubMed 11004671

Flørenes VA, Faye RS, Maelandsmo GM, Nesland JM, Holm R (2000)
Levels of cyclin D1 and D3 in malignant melanoma: deregulated cyclin D3 expression is associated with poor clinical outcome in superficial melanoma
Clin Cancer Res, 6 (9), 3614-20
PubMed 10999753

Holm R (2000)
A highly sensitive nonisotopic detection method for in situ hybridization
Appl Immunohistochem Mol Morphol, 8 (2), 162-5
DOI 10.1097/00129039-200006000-00012, PubMed 10937065

De Jonge ET, Lindeque BG, Burger W, Nesland JM, Holm R (2000)
Predicting response to neoadjuvant chemotherapy in patients with cervical carcinoma: can we do without any longer?
Int J Gynecol Cancer, 10 (2), 137-142
DOI 10.1046/j.1525-1438.2000.00022.x, PubMed 11240665

Baekelandt MM, Holm R, Nesland JM, Tropé CG, Kristensen GB (2000)
P-glycoprotein expression is a marker for chemotherapy resistance and prognosis in advanced ovarian cancer
Anticancer Res, 20 (2B), 1061-7
PubMed 10810398

Baekelandt M, Holm R, Tropé CG, Nesland JM, Kristensen GB (1999)
The significance of metastasis-related factors cathepsin-D and nm23 in advanced ovarian cancer
Ann Oncol, 10 (11), 1335-41
DOI 10.1023/a:1008352502465, PubMed 10631462

Baekelandt M, Holm R, Tropé CG, Nesland JM, Kristensen GB (1999)
Lack of independent prognostic significance of p21 and p27 expression in advanced ovarian cancer: an immunohistochemical study
Clin Cancer Res, 5 (10), 2848-53
PubMed 10537352

Hennig EM, Di Lonardo A, Venuti A, Holm R, Marcante ML, Nesland JM (1999)
HPV 16 in multiple neoplastic lesions in women with CIN III
J Exp Clin Cancer Res, 18 (3), 369-77
PubMed 10606184

Reed W, Flørems VA, Holm R, Hannisdal E, Nesland JM (1999)
Elevated levels of p27, p21 and cyclin D1 correlate with positive oestrogen and progesterone receptor status in node-negative breast carcinoma patients
Virchows Arch, 435 (2), 116-24
DOI 10.1007/s004280050408, PubMed 10599310

Baekelandt M, Kristensen GB, Nesland JM, Tropé CG, Holm R (1999)
Clinical significance of apoptosis-related factors p53, Mdm2, and Bcl-2 in advanced ovarian cancer
J Clin Oncol, 17 (7), 2061
DOI 10.1200/JCO.1999.17.7.2061, PubMed 10561259

De Jonge ET, Viljoen E, Lindeque BG, Amant F, Nesland JM, Holm R (1999)
The prognostic significance of p53, mdm2, c-erbB-2, cathepsin D, and thrombocytosis in stage IB cervical cancer treated by primary radical hysterectomy
Int J Gynecol Cancer, 9 (3), 198-205
DOI 10.1046/j.1525-1438.1999.99019.x, PubMed 11240767

Skomedal H, Kristensen GB, Lie AK, Holm R (1999)
Aberrant expression of the cell cycle associated proteins TP53, MDM2, p21, p27, cdk4, cyclin D1, RB, and EGFR in cervical carcinomas
Gynecol Oncol, 73 (2), 223-8
DOI 10.1006/gyno.1999.5346, PubMed 10329038

Skomedal H, Kristensen GB, Nesland JM, Børresen-Dale AL, Tropé C, Holm R (1999)
TP53 alterations in relation to the cell cycle-associated proteins p21, cyclin D1, CDK4, RB, MDM2, and EGFR in cancers of the uterine corpus
J Pathol, 187 (5), 556-62
DOI 10.1002/(SICI)1096-9896(199904)187:5<556::AID-PATH294>3.0.CO;2-Y, PubMed 10398121

Skomedal H, Helland A, Kristensen GB, Holm R, Børresen-Dale AL (1999)
Allelic imbalance at chromosome region 11q23 in cervical carcinomas
Eur J Cancer, 35 (4), 659-63
DOI 10.1016/s0959-8049(98)00413-4, PubMed 10492643

Lie AK, Skarsvåg S, Skomedal H, Haugen OA, Holm R (1999)
Expression of p53, MDM2, and p21 proteins in high-grade cervical intraepithelial neoplasia and relationship to human papillomavirus infection
Int J Gynecol Pathol, 18 (1), 5-11
DOI 10.1097/00004347-199901000-00002, PubMed 9891236

Hennig EM, Kvinnsland S, Holm R, Nesland JM (1999)
Significant difference in p53 and p21 protein immunoreactivity in HPV 16 positive and HPV negative breast carcinomas
Acta Oncol, 38 (7), 931-8
DOI 10.1080/028418699432617, PubMed 10606422

Hennig EM, Suo Z, Karlsen F, Holm R, Thoresen S, Nesland JM (1999)
HPV positive bronchopulmonary carcinomas in women with previous high-grade cervical intraepithelial neoplasia (CIN III)
Acta Oncol, 38 (5), 639-47
DOI 10.1080/028418699431258, PubMed 10427955

Hennig EM, Suo Z, Thoresen S, Holm R, Kvinnsland S, Nesland JM (1999)
Human papillomavirus 16 in breast cancer of women treated for high grade cervical intraepithelial neoplasia (CIN III)
Breast Cancer Res Treat, 53 (2), 121-35
DOI 10.1023/a:1006162609420, PubMed 10326789

Baekelandt M, Kristensen GB, Tropé CG, Nesland JM, Holm R (1999)
Epidermal growth factor receptor expression has no independent prognostic significance in advanced ovarian cancer
Anticancer Res, 19 (5C), 4469-74
PubMed 10650794

Smith-Sørensen B, Kaern J, Holm R, Dørum A, Tropé C, Børresen-Dale AL (1998)
Therapy effect of either paclitaxel or cyclophosphamide combination treatment in patients with epithelial ovarian cancer and relation to TP53 gene status
Br J Cancer, 78 (3), 375-81
DOI 10.1038/bjc.1998.502, PubMed 9703286

Helland A, Karlsen F, Due EU, Holm R, Kristensen G, Børresen-Dale Al (1998)
Mutations in the TP53 gene and protein expression of p53, MDM 2 and p21/WAF-1 in primary cervical carcinomas with no or low human papillomavirus load
Br J Cancer, 78 (1), 69-72
DOI 10.1038/bjc.1998.444, PubMed 9662253

Flørenes VA, Maelandsmo GM, Kerbel RS, Slingerland JM, Nesland JM, Holm R (1998)
Protein expression of the cell-cycle inhibitor p27Kip1 in malignant melanoma: inverse correlation with disease-free survival
Am J Pathol, 153 (1), 305-12
DOI 10.1016/S0002-9440(10)65572-1, PubMed 9665492

Sørlie T, Martel-Planche G, Hainaut P, Lewalter J, Holm R, Børresen-Dale AL, Montesano R (1998)
Analysis of p53, p16MTS, p21WAF1 and H-ras in archived bladder tumours from workers exposed to aromatic amines
Br J Cancer, 77 (10), 1573-9
DOI 10.1038/bjc.1998.259, PubMed 9635831

Kalantari M, Karlsen F, Kristensen G, Holm R, Hagmar B, Johansson B (1998)
Disruption of the E1 and E2 reading frames of HPV 16 in cervical carcinoma is associated with poor prognosis
Int J Gynecol Pathol, 17 (2), 146-53
DOI 10.1097/00004347-199804000-00009, PubMed 9553812

Ohlckers P, Holm R, Jakobsen H, Kvisteroy T, Kittilsland G, Larsen A, Nese M, Nilsen SM, Ferber A (1998)
An integrated resonant accelerometer microsystem for automotive applications
Sens. Actuator A-Phys., 66 (1-3), 99-104
DOI 10.1016/S0924-4247(97)01734-2

Kareem BN, Karlsen F, Holm R, Hennig EM, Suo Z, Emilsen E, Hellesylt E, Nesland JM (1997)
A novel grid polymerase chain reaction (G-PCR) approach at ultrastructural level to detect target DNA in cell cultures and tissues
J Pathol, 183 (4), 486-93
DOI 10.1002/(SICI)1096-9896(199712)183:4<486::AID-PATH945>3.0.CO;2-D, PubMed 9496267

Zhang ZY, Sue ZH, Sudbo J, Holm R, Boysen M, Reith A (1997)
Diagnostic implications of p53 protein reactivity in nasal mucosa of nickel workers
Anal. Quant. Cytol. Histol., 19 (4), 345-350

Zhang Z, Suo Z, Sudbø J, Holm R, Boysen M, Reith A (1997)
Diagnostic implications of p53 protein reactivity in nasal mucosa of nickel workers
Anal Quant Cytol Histol, 19 (4), 345-50
PubMed 9267568

Berner A, Franzén S, Holm R (1997)
HPV 16 infection in a patient with two primary squamous cell carcinomas: of the uterine cervix and the anal mucosa
APMIS, 105 (3), 207-12
DOI 10.1111/j.1699-0463.1997.tb00560.x, PubMed 9137516

Skomedal H, Kristensen GB, Abeler VM, Børresen-Dale AL, Tropé C, Holm R (1997)
TP53 protein accumulation and gene mutation in relation to overexpression of MDM2 protein in ovarian borderline tumours and stage I carcinomas
J Pathol, 181 (2), 158-65
DOI 10.1002/(SICI)1096-9896(199702)181:2<158::AID-PATH742>3.0.CO;2-8, PubMed 9120719

Kraggerud SM, Jacobsen KD, Berner A, Stokke T, Holm R, Smedshammer L, Børresen-Dale AL, Fosså SD (1997)
A comparison of different modes for the detection of p53 protein accumulation. A study of bladder cancer
Pathol Res Pract, 193 (7), 471-8
DOI 10.1016/s0344-0338(97)80099-4, PubMed 9342752

Ohlckers P, Holm R, Jakobsen H, Kvisteroy T, Kittilsland G, Nese M, Nilsen SM, Ferber A (1997)
An integrated resonant accelerometer microsystem for automotive applications
TRANSDUCERS 97 - 1997 INTERNATIONAL CONFERENCE ON SOLID-STATE SENSORS AND ACTUATORS, DIGEST OF TECHNICAL PAPERS, VOLS 1 AND 2, 843-846

Holm R, Flørenes VA, Erikstein B, Nesland JM (1997)
Expression of stromelysin-3 in medullary carcinoma of the breast
Anticancer Res, 17 (5B), 3725-7
PubMed 9427769

Maelandsmo GM, Holm R, Fodstad O, Kerbel RS, Flørenes VA (1996)
Cyclin kinase inhibitor p21WAF1/CIP1 in malignant melanoma: reduced expression in metastatic lesions
Am J Pathol, 149 (6), 1813-22
PubMed 8952518

Lie ES, Karlsen F, Holm R (1996)
Presence of human papillomavirus in squamous cell laryngeal carcinomas. A study of thirty-nine cases using polymerase chain reaction and in situ hybridization
Acta Otolaryngol, 116 (6), 900-5
DOI 10.3109/00016489609137949, PubMed 8973730

Karlsen F, Kalantari M, Jenkins A, Pettersen E, Kristensen G, Holm R, Johansson B, Hagmar B (1996)
Use of multiple PCR primer sets for optimal detection of human papillomavirus
J Clin Microbiol, 34 (9), 2095-100
DOI 10.1128/jcm.34.9.2095-2100.1996, PubMed 8862564

Kristensen GB, Holm R, Abeler VM, Tropé CG (1996)
Evaluation of the prognostic significance of cathepsin D, epidermal growth factor receptor, and c-erbB-2 in early cervical squamous cell carcinoma. An immunohistochemical study
Cancer, 78 (3), 433-40
DOI 10.1002/(SICI)1097-0142(19960801)78:3<433::AID-CNCR9>3.0.CO;2-K, PubMed 8697388

Kristensen GB, Holm R, Abeler VM, Tropé CG (1996)
Evaluation of the prognostic significance of nm23/NDP kinase protein expression in cervical carcinoma: an immunohistochemical study
Gynecol Oncol, 61 (3), 378-83
DOI 10.1006/gyno.1996.0160, PubMed 8641619

Holm R, Tanum G (1996)
Evaluation of the prognostic significance of nm23/NDP kinase and cathepsin D in anal carcinomas. An immunohistochemical study
Virchows Arch, 428 (2), 85-9
DOI 10.1007/BF00193935, PubMed 8925129

Maelandsmo GM, Flørenes VA, Hovig E, Oyjord T, Engebraaten O, Holm R, Børresen AL, Fodstad O (1996)
Involvement of the pRb/p16/cdk4/cyclin D1 pathway in the tumorigenesis of sporadic malignant melanomas
Br J Cancer, 73 (8), 909-16
DOI 10.1038/bjc.1996.181, PubMed 8611425

Chitemerere M, Andersen TI, Holm R, Karlsen F, Børresen AL, Nesland JM (1996)
TP53 alterations in atypical ductal hyperplasia and ductal carcinoma in situ of the breast
Breast Cancer Res Treat, 41 (2), 103-9
DOI 10.1007/BF01807155, PubMed 8944328

Tanum G, Holm R (1996)
Anal carcinoma: a clinical approach to p53 and RB gene proteins
Oncology, 53 (5), 369-73
DOI 10.1159/000227590, PubMed 8784470

Skomedal H, Kristensen G, Holm R (1995)
Expression of retinoblastoma tumor suppressor gene protein, epidermal growth factor receptor, and c-erbB-2 oncoprotein in primary vaginal carcinomas
Gynecol Oncol, 59 (3), 379-83
DOI 10.1006/gyno.1995.9958, PubMed 8522259

Skomedal H, Kristensen G, Helland A, Nesland JM, Kooi S, Børresen AL, Holm R (1995)
TP53 gene mutations and protein accumulation in primary vaginal carcinomas
Br J Cancer, 72 (1), 129-33
DOI 10.1038/bjc.1995.288, PubMed 7599041

Flørenes VA, Holm R, Fodstad O (1995)
Accumulation of p53 protein in human malignant melanoma. Relationship to clinical outcome
Melanoma Res, 5 (3), 183-7
DOI 10.1097/00008390-199506000-00007, PubMed 7640520

Holm R (1995)
Null cell adenomas and oncocytomas of the pituitary gland
Pathol Res Pract, 191 (4), 348-52
DOI 10.1016/S0344-0338(11)80888-5, PubMed 7479351

Karlsen F, Kristensen G, Holm R, Chitemerere M, Berner A, Hagmar BM (1995)
High incidence of human papillomavirus in 146 cervical carcinomas. A study using three different pairs of consensus primers, and detecting viral genomes with putative deletions
Eur J Cancer, 31A (9), 1511-6
DOI 10.1016/0959-8049(95)00206-x, PubMed 7577081

Holm R, Høie J, Kaalhus O, Nesland JM (1995)
Immunohistochemical detection of nm23/NDP kinase and cathepsin D in medullary carcinomas of the thyroid gland
Virchows Arch, 427 (3), 289-94
DOI 10.1007/BF00203397, PubMed 7496599

Lopes JM, Bjerkehagen B, Holm R, Bruland O, Sobrinho-Simões M, Nesland JM (1995)
Proliferative activity of synovial sarcoma: an immunohistochemical evaluation of Ki-67 labeling indices of 52 primary and recurrent tumors
Ultrastruct Pathol, 19 (2), 101-6
DOI 10.3109/01913129509014609, PubMed 7792946

Suo Z, Su W, Holm R, Nesland JM (1995)
Lack of expression of c-erbB-2 oncoprotein in human esophageal squamous cell carcinomas
Anticancer Res, 15 (6B), 2797-8
PubMed 8669867

Holm R, Nesland JM (1994)
[Microwave oven in immunohistochemistry. An important tool for determination of antigens in formalin-fixed and paraffin-embedded tissue]
Tidsskr Nor Laegeforen, 114 (20), 2392-4
PubMed 7527943

Holm R, Tanum G, Karlsen F, Nesland JM (1994)
Prevalence and physical state of human papillomavirus DNA in anal carcinomas
Mod Pathol, 7 (4), 449-53
PubMed 8066073

Makar AP, Holm R, Kristensen GB, Nesland JM, Tropé CG (1994)
The expression of c-erbB-2 (HER-2/neu) oncogene in invasive ovarian malignancies
Int J Gynecol Cancer, 4 (3), 194-199
DOI 10.1046/j.1525-1438.1994.04030194.x, PubMed 11578406

Kristiansen E, Jenkins A, Holm R (1994)
Coexistence of episomal and integrated HPV16 DNA in squamous cell carcinoma of the cervix
J Clin Pathol, 47 (3), 253-6
DOI 10.1136/jcp.47.3.253, PubMed 7677803

Holm R, Nesland JM (1994)
Retinoblastoma and p53 tumour suppressor gene protein expression in carcinomas of the thyroid gland
J Pathol, 172 (3), 267-72
DOI 10.1002/path.1711720307, PubMed 8195930

David L, Nesland JM, Holm R, Sobrinho-Simões M (1994)
Expression of laminin, collagen IV, fibronectin, and type IV collagenase in gastric carcinoma. An immunohistochemical study of 87 patients
Cancer, 73 (3), 518-27
DOI 10.1002/1097-0142(19940201)73:3<518::aid-cncr2820730305>3.0.co;2-t, PubMed 8299074

Lopes JM, Bjerkehagen B, Holm R, Bruland O, Sobrinho-Simões M, Nesland JM (1994)
Immunohistochemical profile of synovial sarcoma with emphasis on the epithelial-type differentiation. A study of 49 primary tumours, recurrences and metastases
Pathol Res Pract, 190 (2), 168-77
DOI 10.1016/S0344-0338(11)80708-9, PubMed 7520165

Flørenes VA, Oyjord T, Holm R, Skrede M, Børresen AL, Nesland JM, Fodstad O (1994)
TP53 allele loss, mutations and expression in malignant melanoma
Br J Cancer, 69 (2), 253-9
DOI 10.1038/bjc.1994.48, PubMed 7905277

Abeler VM, Holm R, Nesland JM, Kjørstad KE (1994)
Small cell carcinoma of the cervix. A clinicopathologic study of 26 patients
Cancer, 73 (3), 672-7
DOI 10.1002/1097-0142(19940201)73:3<672::aid-cncr2820730328>3.0.co;2-r, PubMed 8299089

Bjerkehagen B, Fosså SD, Raabe N, Holm R, Nesland JM (1994)
Transitional cell carcinoma of the renal pelvis and its expression of p53 protein, c-erbB-2 protein, neuron-specific enolase, Phe 5, chromogranin, laminin and collagen type IV
Eur Urol, 26 (4), 334-9
DOI 10.1159/000475410, PubMed 7713133

Helland A, Holm R, Kristensen G, Kaern J, Karlsen F, Trope C, Nesland JM, Børresen AL (1993)
Genetic alterations of the TP53 gene, p53 protein expression and HPV infection in primary cervical carcinomas
J Pathol, 171 (2), 105-14
DOI 10.1002/path.1711710207, PubMed 8283348

Andersen TI, Holm R, Nesland JM, Heimdal KR, Ottestad L, Børresen AL (1993)
Prognostic significance of TP53 alterations in breast carcinoma
Br J Cancer, 68 (3), 540-8
DOI 10.1038/bjc.1993.383, PubMed 8102535

Suo Z, Holm R, Nesland JM (1993)
Squamous cell carcinomas. An immunohistochemical study of cytokeratins and involucrin in primary and metastatic tumours
Histopathology, 23 (1), 45-54
DOI 10.1111/j.1365-2559.1993.tb01182.x, PubMed 7690007

Holm R, Abeler VM, Skomedal H, Nesland JM (1993)
Overexpression of p53 protein and c-erbB-2 protein in small cell carcinoma of the cervix uteri
Zentralbl Pathol, 139 (2), 153-6
PubMed 8103676

Heimdal K, Lothe RA, Lystad S, Holm R, Fosså SD, Børresen AL (1993)
No germline TP53 mutations detected in familial and bilateral testicular cancer
Genes Chromosomes Cancer, 6 (2), 92-7
DOI 10.1002/gcc.2870060205, PubMed 7680893

Helseth A, Bautch VL, Haug E, Holm R, Nesland JM, Fodstad O (1993)
[Transgenic mice as animal model of Cushing's syndrome]
Tidsskr Nor Laegeforen, 113 (2), 206-10
PubMed 8381565

Suo Z, Qvist H, Su W, Holm R, Giercksky KE, Nesland JM (1993)
Undifferentiated carcinoma: an immunohistochemical and ultrastructural study
Anticancer Res, 13 (3), 643-9
PubMed 8317892

Holm R, Skomedal H, Helland A, Kristensen G, Børresen AL, Nesland JM (1993)
Immunohistochemical analysis of p53 protein overexpression in normal, premalignant, and malignant tissues of the cervix uteri
J Pathol, 169 (1), 21-6
DOI 10.1002/path.1711690105, PubMed 8433212

Holm R, Helseth A, Nesland JM, Bautch VL (1993)
ACTH-producing pituitary tumors in transgenic mice. An ultrastructural and immunoelectron microscopic study
J Submicrosc Cytol Pathol, 25 (1), 29-36
PubMed 8384929

Berner A, Holm R, Naess A, Hjortdal O (1993)
p53 protein expression in squamocellular carcinomas of the lip
Anticancer Res, 13 (6B), 2421-4
PubMed 8135477

Gorczyca W, Holm R, Nesland JM (1993)
Laminin production and fibronectin immunoreactivity in breast carcinomas
Anticancer Res, 13 (4), 851-8
PubMed 8394677

David L, Seruca R, Nesland JM, Soares P, Sansonetty F, Holm R, Børresen AL, Sobrinho-Simões M (1992)
c-erbB-2 expression in primary gastric carcinomas and their metastases
Mod Pathol, 5 (4), 384-90
PubMed 1353880

Holm R, Karlsen F, Nesland JM (1992)
In situ hybridization with nonisotopic probes using different detection systems
Mod Pathol, 5 (3), 315-9
PubMed 1323105

Suo Z, Holm R, Nesland JM (1992)
Squamous cell carcinomas, an immunohistochemical and ultrastructural study
Anticancer Res, 12 (6B), 2025-31
PubMed 1284199

Nesland JM, Ottestad L, Heikilla R, Holm R, Tveit K, Børresen AL (1991)
C-erbB-2 protein and neuroendocrine expression in breast carcinomas
Anticancer Res, 11 (1), 161-7
PubMed 1673329

Nesland JM, Ottestad L, Børresen AL, Tvedt KE, Holm R, Heikkilä R, Tveit K (1991)
The c-erbB-2 protein in primary and metastatic breast carcinomas
Ultrastruct Pathol, 15 (3), 281-9
DOI 10.3109/01913129109021890, PubMed 1678562

Sobrinho-Simoes M, Sambade C, Nesland JM, Holm R, Damjanov I (1990)
Lectin histochemistry and ultrastructure of medullary carcinoma of the thyroid gland
Arch Pathol Lab Med, 114 (4), 369-75
PubMed 1690976

Dasović-Knezević M, Børmer O, Holm R, Høie J, Sobrinho-Simões M, Nesland JM (1989)
Carcinoembryonic antigen in medullary thyroid carcinoma: an immunohistochemical study applying six novel monoclonal antibodies
Mod Pathol, 2 (6), 610-7
PubMed 2587568

Holm R, Nesland JM, Attramadal A, Halse J, Johannessen JV (1989)
Null cell adenomas of the pituitary gland. An immunohistochemical study
J Pathol, 158 (3), 213-7
DOI 10.1002/path.1711580307, PubMed 2769482

KOTANSKA KM, HOLM R, OTTESTAD L, NESLAND JM (1989)
AN ULTRASTRUCTURAL-STUDY OF BENIGN AND MALIGNANT BREAST EPITHELIAL-CELLS - A SEARCH FOR TONOFILAMENTS
J. Submicrosc. Cytol. Pathol., 21 (3), 469-474

Kotańska KM, Holm R, Ottestad L, Nesland JM (1989)
An ultrastructural study of benign and malignant breast epithelial cells. A search for tonofilaments
J Submicrosc Cytol Pathol, 21 (3), 469-74
PubMed 2551480

Holm R, Nesland JM, Attramadal A, Reinli S, Johannessen JV (1989)
Mixed growth hormone- and prolactin cell adenomas of the pituitary gland. An immunoelectron microscopic study
J Submicrosc Cytol Pathol, 21 (2), 339-50
PubMed 2752363

Holm R, Farrants GW, Nesland JM, Sobrinho-Simões M, Jørgensen OG, Johannessen JV (1989)
Ultrastructural and electron immunohistochemical features of medullary thyroid carcinoma
Virchows Arch A Pathol Anat Histopathol, 414 (5), 375-84
DOI 10.1007/BF00718620, PubMed 2499093

Nesland JM, Holm R, Johannessen JV, Gould VE (1988)
Neuroendocrine differentiation in breast lesions
Pathol Res Pract, 183 (2), 214-21
DOI 10.1016/S0344-0338(88)80048-7, PubMed 3290869

Holm R, Nesland JM, Attramadal A, Johannessen JV (1988)
Double-staining methods at the ultrastructural level applying colloidal gold conjugates
Ultrastruct Pathol, 12 (3), 279-90
DOI 10.3109/01913128809098040, PubMed 2456636

Holm R, Varndell IM, Power RF, Bishop AE, Madsen OD, Alpert S, Hanahan D, Polak JM (1988)
Ultrastructure and electron immunocytochemistry of insulin-producing B-cell tumors from transgenic mice: comparison with counterpart human tumors
Ultrastruct Pathol, 12 (5), 547-59
DOI 10.3109/01913128809032239, PubMed 2848349

NESLAND JM, HOLM R, OTTESTAD L, KARLSEN KO, JOHANNESSEN JV (1988)
NEURO-ENDOCRINE ACTIVITY IN METASTATIC BREAST CARCINOMAS
APMIS, 96 2, 204-214

Nesland JM, Holm R, Ottestad L, Karlsen KO, Johannessen JV (1988)
Neuroendocrine activity in metastatic breast carcinomas
APMIS Suppl, 2, 204-14
PubMed 2846016

Lunde S, Nesland JM, Holm R, Johannessen JV (1987)
Breast carcinomas with protein S-100 immunoreactivity. An immunocytochemical and ultrastructural study
Pathol Res Pract, 182 (5), 627-31
PubMed 2825146

Holm R, Sobrinho-Simões M, Nesland JM, Sambade C, Johannessen JV (1987)
Medullary thyroid carcinoma with thyroglobulin immunoreactivity. A special entity?
Lab Invest, 57 (3), 258-68
PubMed 3626517

Lunde S, Nesland JM, Holm R, Johannessen JV (1987)
A urinary bladder tumor in a 65-year-old man
Ultrastruct Pathol, 11 (1), 79-82
DOI 10.3109/01913128709023186, PubMed 3824568

Nesland JM, Holm R, Lunde S, Johannessen JV (1987)
Diagnostic problems in breast pathology: the benefit of ultrastructural and immunocytochemical analysis
Ultrastruct Pathol, 11 (2-3), 293-311
DOI 10.3109/01913128709048328, PubMed 3035768

Power RF, Holm R, Bishop AE, Varndell IM, Alpert S, Hanahan D, Polak JM (1987)
Transgenic mouse model: a new approach for the investigation of endocrine pancreatic B-cell growth
Gut, 28 Suppl (Suppl), 121-9
DOI 10.1136/gut.28.suppl.121, PubMed 2826309

Nesland JM, Lunde S, Holm R, Johannessen JV (1987)
Electron microscopy and immunostaining of the normal breast and its benign lesions. A search for neuroendocrine cells
Histol Histopathol, 2 (1), 73-7
PubMed 2980706

Kjellevold K, Nesland JM, Holm R, Johannessen JV (1986)
Multicystic peritoneal mesothelioma
Pathol Res Pract, 181 (6), 767-73
DOI 10.1016/S0344-0338(86)80056-5, PubMed 2436202

Nesland JM, Holm R, Johannessen JV (1986)
A study of different markers for neuroendocrine differentiation in breast carcinomas
Pathol Res Pract, 181 (5), 524-30
DOI 10.1016/S0344-0338(86)80144-3, PubMed 2431399

Sobrinho-Simões M, Stenwig AE, Nesland JM, Holm R, Johannessen JV (1986)
A mucinous carcinoma of the thyroid
Pathol Res Pract, 181 (4), 464-71
DOI 10.1016/S0344-0338(86)80086-3, PubMed 3020530

Sand O, Jonsson L, Nielsen M, Holm R, Gautvik KM (1986)
Electrophysiological properties of calcitonin-secreting cells derived from human medullary thyroid carcinoma
Acta Physiol Scand, 126 (2), 173-9
DOI 10.1111/j.1748-1716.1986.tb07803.x, PubMed 3705981

Nesland JM, Holm R, Johannessen JV (1986)
Spindle cell tumor in the breast
Ultrastruct Pathol, 10 (5), 415-9
DOI 10.3109/01913128609007195, PubMed 2429416

Nesland JM, Holm R, Johannessen JV, Gould VE (1986)
Neurone specific enolase immunostaining in the diagnosis of breast carcinomas with neuroendocrine differentiation. Its usefulness and limitations
J Pathol, 148 (1), 35-43
DOI 10.1002/path.1711480107, PubMed 3003312

Lunde S, Nesland JM, Holm R, Johannessen JV (1986)
Primary malignant fibrous histiocytoma of the breast
Histol Histopathol, 1 (1), 27-32
PubMed 2856533

NESLAND JM, HOLM R, JOHANNESSEN JV (1986)
ELECTRON-MICROSCOPY AND IMMUNOCYTOCHEMISTRY IN DIAGNOSTIC TUMOR PATHOLOGY
J ELECTRON MICR TECH, 4 (2), 130-142
DOI 10.1002/jemt.1060040208

Holm R, Sobrinho-Simões M, Nesland JM, Johannessen JV (1986)
Concurrent production of calcitonin and thyroglobulin by the same neoplastic cells
Ultrastruct Pathol, 10 (3), 241-8
DOI 10.3109/01913128609032223, PubMed 3715999

Holm R, Gaarder PI, Helgeland L, Falkenhaug EI (1985)
A human autoantibody to peroxisomes
Clin Exp Immunol, 61 (2), 305-14
PubMed 3899430

Nesland JM, Holm R, Johannessen JV (1985)
Ultrastructural and immunohistochemical features of lobular carcinoma of the breast
J Pathol, 145 (1), 39-52
DOI 10.1002/path.1711450104, PubMed 2578561

Nesland JM, Sobrinho-Simões MA, Holm R, Johannessen JV (1985)
Organoid tumor in the thyroid gland
Ultrastruct Pathol, 9 (1-2), 65-70
DOI 10.3109/01913128509055487, PubMed 4089997

Sobrinho-Simões MA, Nesland JM, Holm R, Sambade MC, Johannessen JV (1985)
Hürthle cell and mitochondrion-rich papillary carcinomas of the thyroid gland: an ultrastructural and immunocytochemical study
Ultrastruct Pathol, 8 (2-3), 131-42
DOI 10.3109/01913128509142147, PubMed 4060255

Nesland JM, Sobrinho-Simões MA, Holm R, Johannessen JV (1985)
Primitive neuroectodermal tumor (peripheral neuroblastoma)
Ultrastruct Pathol, 9 (1-2), 59-64
DOI 10.3109/01913128509055486, PubMed 3003993

Nesland JM, Memoli VA, Holm R, Gould VE, Johannessen JV (1985)
Breast carcinomas with neuroendocrine differentiation
Ultrastruct Pathol, 8 (2-3), 225-40
DOI 10.3109/01913128509142155, PubMed 4060259

Holm R, Sobrinho-Simões M, Nesland JM, Gould VE, Johannessen JV (1985)
Medullary carcinoma of the thyroid gland: an immunocytochemical study
Ultrastruct Pathol, 8 (1), 25-41
DOI 10.3109/01913128509141506, PubMed 3901454

Nesland JM, Sobrinho-Simões MA, Holm R, Sambade MC, Johannessen JV (1985)
Hürthle-cell lesions of the thyroid: a combined study using transmission electron microscopy, scanning electron microscopy, and immunocytochemistry
Ultrastruct Pathol, 8 (4), 269-90
DOI 10.3109/01913128509141518, PubMed 4082297

Sobrinho-Simões MA, Nesland JM, Holm R, Johannessen JV (1985)
Transmission electron microscopy and immunocytochemistry in the diagnosis of thyroid tumors
Ultrastruct Pathol, 9 (3-4), 255-75
DOI 10.3109/01913128509074581, PubMed 3911530

Review articles

Abrahamsson B, McAllister M, Augustijns P, Zane P, Butler J, Holm R, Langguth P, Lindahl A, Müllertz A, Pepin X, Rostami-Hodjegan A, Sjögren E, Berntsson M, Lennernäs H (2020)
Six years of progress in the oral biopharmaceutics area - A summary from the IMI OrBiTo project
Eur J Pharm Biopharm, 152, 236-247
DOI 10.1016/j.ejpb.2020.05.008, PubMed 32446960

Nguyen MA, Flanagan T, Brewster M, Kesisoglou F, Beato S, Biewenga J, Crison J, Holm R, Li R, Mannaert E, McAllister M, Mueller-Zsigmondy M, Muenster U, Ojala K, Page S, Parr A, Rossenu S, Timmins P, Van Peer A, Vermeulen A, Langguth P (2017)
A survey on IVIVC/IVIVR development in the pharmaceutical industry - Past experience and current perspectives
Eur J Pharm Sci, 102, 1-13
DOI 10.1016/j.ejps.2017.02.029, PubMed 28235611

Lennernäs H, Aarons L, Augustijns P, Beato S, Bolger M, Box K, Brewster M, Butler J, Dressman J, Holm R, Julia Frank K, Kendall R, Langguth P, Sydor J, Lindahl A, McAllister M, Muenster U, Müllertz A, Ojala K, Pepin X, Reppas C, Rostami-Hodjegan A, Verwei M, Weitschies W, Wilson C et al. (2013)
Oral biopharmaceutics tools - time for a new initiative - an introduction to the IMI project OrBiTo
Eur J Pharm Sci, 57, 292-9
DOI 10.1016/j.ejps.2013.10.012, PubMed 24189462

Knopp S, Tropè C, Nesland JM, Holm R (2009)
A review of molecular pathological markers in vulvar carcinoma: lack of application in clinical practice
J Clin Pathol, 62 (3), 212-8
DOI 10.1136/jcp.2008.057240, PubMed 19251952

Wang Y, Kristensen GB, Helland A, Nesland JM, Børresen-Dale AL, Holm R (2005)
Protein expression and prognostic value of genes in the erb-b signaling pathway in advanced ovarian carcinomas
Am J Clin Pathol, 124 (3), 392-401
DOI 10.1309/BL7E-MW66-LQX6-GFRP, PubMed 16191507

Holm R (2005)
In situ hybridization methods to study microbial populations and their interactions with human host cells
Methods Microbiol., 34, 1-+
DOI 10.1016/S0580-9517(04)34001-8

Lopes JM, Bruland OS, Bjerkehagen B, Silva MC, Holm R, Pettersen EO, Solheim OP, Sobrinho-Simões M, Nesland JM (1997)
Synovial sarcoma: immunohistochemical expression of P-glycoprotein and glutathione S transferase-pi and clinical drug resistance
Pathol Res Pract, 193 (1), 21-36
DOI 10.1016/s0344-0338(97)80090-8, PubMed 9112270